ResearcherKlinikum KlagenfurtNo recent work listed
Wolfgang Eisterer
Matched on ORCID iD 0000-0003-1244-7275; OpenAlex author ID A5061264691. Sources: OpenAlex.
Their work
- Papers
- 3 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 7
2019: 1 paper · 2020: 1 paper · 2021: 1 paper
Papers 3
- Comparison of nab-paclitaxel plus gemcitabine in elderly versus younger patients with metastatic pancreatic cancer: Analysis of a multicentre, prospective, non… Last author DOI 10.1016/j.ejca.2020.11.003↗
- The AST/ALT (De Ritis) ratio predicts clinical outcome in patients with pancreatic cancer treated with first-line nab-paclitaxel and gemcitabine: post hoc anal… Co-author DOI 10.1177/1758835919900872↗
- Patterns of care in metastatic pancreatic cancer: patient selection in clinical routine. Co-author DOI 10.1177/1756284819877635↗
Closest collaborators
The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Gerald W. Prager · 3 shared papers, 2019–2021 · strength 0.28
- Paper Comparison of nab-paclitaxel plus gemcitabine in elderly versus younger patients with metastatic pancreatic cancer: Ana… DOI 10.1016/j.ejca.2020.11.003↗
- Paper Patterns of care in metastatic pancreatic cancer: patient selection in clinical routine. DOI 10.1177/1756284819877635↗
- Paper The AST/ALT (De Ritis) ratio predicts clinical outcome in patients with pancreatic cancer treated with first-line nab-p… DOI 10.1177/1758835919900872↗
- Armin Gerger · 2 shared papers, 2020–2021 · strength 0.18
- Paper Comparison of nab-paclitaxel plus gemcitabine in elderly versus younger patients with metastatic pancreatic cancer: Ana… DOI 10.1016/j.ejca.2020.11.003↗
- Paper The AST/ALT (De Ritis) ratio predicts clinical outcome in patients with pancreatic cancer treated with first-line nab-p… DOI 10.1177/1758835919900872↗
- Richard Greil · 2 shared papers, 2019–2020 · strength 0.18
- Werner Scheithauer · 1 shared paper, 2019 · strength 0.10
- Paul Martin Putora · 1 shared paper, 2019 · strength 0.10
- Markus Glatzer · 1 shared paper, 2019 · strength 0.10
- Jakob Michael Riedl · 1 shared paper, 2020 · strength 0.08
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.